Achieve Life Sciences, Inc.
ACHV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $229 | $0 | $0 | $0 |
| Gross Profit | -$229 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $22,817 | $15,814 | $30,078 | $23,966 |
| G&A Expenses | $16,252 | $11,436 | $10,722 | $9,128 |
| SG&A Expenses | $16,252 | $11,436 | $10,722 | $9,128 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$229 | $0 | $0 | $0 |
| Operating Expenses | $38,840 | $27,250 | $40,800 | $33,094 |
| Operating Income | -$39,069 | -$27,250 | -$40,800 | -$33,094 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$758 | -$2,565 | -$1,550 | -$58 |
| Pre-Tax Income | -$39,827 | -$29,815 | -$42,350 | -$33,152 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$39,827 | -$29,815 | -$42,350 | -$33,152 |
| % Margin | – | – | – | – |
| EPS | -1.24 | -1.5 | -3.95 | -4.05 |
| % Growth | 17.3% | 62% | 2.5% | – |
| EPS Diluted | -1.24 | -1.5 | -3.95 | -4.05 |
| Weighted Avg Shares Out | 32,071 | 19,827 | 10,593 | 8,120 |
| Weighted Avg Shares Out Dil | 32,071 | 19,827 | 10,593 | 8,120 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,356 | $825 | $199 | $17 |
| Interest Expense | $2,180 | $2,853 | $1,789 | $0 |
| Depreciation & Amortization | $229 | $228 | $236 | $250 |
| EBITDA | -$37,418 | -$26,734 | -$40,325 | -$32,902 |
| % Margin | – | – | – | – |